Pneumonia - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Pneumonia - Pipeline Review, H2 2013 market report to its offering
Pneumonia - Pipeline Review, H2 2013


, 'Pneumonia - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Pneumonia.
- A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pneumonia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pneumonia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Shionogi & Co., Ltd.
AstraZeneca PLC
Biotest AG
Dainippon Sumitomo Pharma Co., Ltd.
Rib-X Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
Toyama Chemical Co. Ltd
Wockhardt Limited
Paratek Pharmaceuticals, Inc.
Bayer AG
Basilea Pharmaceutica Ltd.
Flamel Technologies S.A.
Dongwha Pharm Co., Ltd.
LTT Bio-Pharma Co., Ltd.
Synairgen plc
Mucosis B.V.
Aridis Pharmaceuticals LLC
aRigen Pharmaceuticals, Inc.
Sinovac Biotech Ltd.
KaloBios Pharmaceuticals, Inc.
Ancora Pharmaceuticals Inc.
KYORIN Pharmaceutical Co., Ltd.
Trius Therapeutics, Inc.
Tetraphase Pharmaceuticals Inc.
TaiGen Biotechnology Co., Ltd.
Savara, Inc.
Pulmotect, Inc.
Durata Therapeutics Inc.
APEPTICO Forschung und Entwicklung GmbH

To view the table of contents for this market research report please visit